Research Radartracking 901 published studies · 229 human · 5 safety signals · 33 clinical trials · 44 cancer pages · updated Jul 2026Open the Research Map →
Breast Invasive Ductal Carcinoma (IDC): Triple-negative (basal-like)
Last reviewed: 9/15/2025
Applies to: ER–/PR–/HER2– disease.
Summary
Chemo-intensive with immunotherapy in high-risk early disease; ADCs and PARP inhibitors (gBRCA) in metastatic settings.
Pathology & Markers
ER–/PR–/HER2–
PD-L1 CPS subset positive
Biology & Pathways
DNA damage repair defects (gBRCA)
Immune-inflamed microenvironment subset
Clinical Challenges
Higher early relapse risk; brain and visceral metastases.
Need for pCR-oriented neoadjuvant therapy and adjuvant adaptation.
Imaging Notes
Baseline staging for stage II–III; brain MRI if neuro symptoms.